tbuckley/cabot-search huggingface dataset:
Late Mortality in Childhood Cancer: Two Excellent Studies Bring Good News Tempered by Room for Improvement
Authors: Joseph V. Simone
Journal: Journal of Clinical Oncology (2001)

Article Tools EDITORIAL Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.13.3161 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11432881 Late Mortality in Childhood Cancer: Two Excellent Studies Bring Good News Tempered by Room for Improvement Joseph V. SimonexJoseph V. SimoneSearch for articles by this author https://doi.org/10.1200/JCO.2001.19.13.3161 Full Text PDF Figures and Tables "Late Mortality in Childhood Cancer: Two Excellent Studies Bring Good News Tempered by Room for Improvement." Journal of Clinical Oncology, 19(13), pp. 3161–3162© 2001 by American Society of Clinical Oncology
Clinical and subclinical alveolitis in collagen vascular diseases: contribution of alpha 2-macroglobulin levels in BAL fluid
Authors: J B Martinot, B Wallaert, P Y Hatron, C Francis, C Voisin, Y Sibille
Journal: European Respiratory Journal (1989)

The probability that patients with collagen vascular diseases (CVD) will develop fibrosis is unpredictable. Since changes in bronchoalveolar lavage (BAL) cell data can be observed in CVD patients without evidence of lung involvement, we investigated whether the study of soluble components in BAL could help to distinguish CVD patients with lung involvement (n = 15) from those without pulmonary disease (n = 37). Our results demonstrate that the alveolitis observed in patients with overt lung involvement is associated with an increase of BAL alpha 2-macroglobulin (alpha 2-MA). In contrast, the BAL alpha 2-MA levels were found to be normal in CVD patients without evidence of pulmonary disease as well as in CVD patients with overt lung involvement treated with steroids. This was observed even in the presence of high neutrophil or lymphocyte counts in BAL. In conclusion, when neutrophils or lymphocytes accumulate in the lungs of CVD patients without evidence of lung damage, in the majority of patients this cell accumulation is not associated with an increase of BAL soluble components.
Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations
Authors: Vladimir Malinin, Zhili Li, Richard Chapman, Franziska Leifer, Donna Omiatek, Jane Ong, Dan Salvail, Charles Laurent, Walter Perkins
Journal: European Respiratory Journal (2014)

Introduction : In a rat model of acute hypoxia-induced pulmonary arterial hypertension (PAH), inhaled lipid nanoparticle formulations of treprostinil prodrugs (TPD) were found to have a longer duration of activity (>>2h) compared to treprostinil (TRE). TPDs with alkyl chains of lengths C12, C14, and C16 yielded the longest extensions in activity. Here, we evaluated the plasma and lung PK in rats that received a single inhaled dose of these TPDs.   Methods : Nebulized TRE solution and TPD formulations were administered (at 15 nmole/kg) to anesthetized-ventilated rats (6h studies) or to conscious rats by nose-only inhalation (24h studies). TRE and TPD concentrations in lung tissue and plasma were measured by HPLC/MS/MS.   Results : Ventilated rats treated with nebulized TRE had the highest plasma C max  (3.5 ng/ml) which occurred immediately after dosing and measurable levels of TRE were not seen beyond 4h in the plasma and by 6h in the lungs. Ventilated rats treated with nebulized TPDs had plasma TRE C max  values ranging from 0.2 to 0.6 ng/mL. TPD lung levels at 6h ranged from 15 to 60 ng/mL. In the 24h studies, plasma concentrations of TRE when dosed with C14- and C16-TPDs were above 0.1 ng/mL for up to 24h, i.e., levels corresponding to activity in acute hypoxia studies.   Conclusions : Inhaled TPDs are present in the lungs for an extended duration and are associated with the slow, sustained release of TRE into the blood. This PK profile is quite different than inhaled TRE and strongly suggests that long alkyl chain prodrug formulations of TRE will likely have prolonged pulmonary vasodilator activity in humans.
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
Authors: C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski
Journal: Journal of Clinical Oncology (2008)

4000 Background: Efficacy analyses of the randomized phase II OPUS trial have previously failed to show significant improvements in progression-free survival time (PFS) or overall response, although a significantly higher response rate was achieved in patients with good performance status (ECOG 0/1) and a significantly higher curative surgery rate for cetuximab added to FOLFOX versus FOLFOX alone in the first-line treatment of mCRC was observed. KRAS mutation status has been related to the efficacy of anti-epidermal growth factor receptor (anti-EGFR) targeted therapies in different cancer models. Efficacy analyses have been repeated to evaluate the influence of KRAS mutation status in first-line patients treated with standard therapy, with or without cetuximab, under controlled study conditions. Methods: Genomic DNA was isolated from archived tumor material. The KRAS mutation status of codons 12/13 was determined using a sensitive, quantitative PCR-based assay. Best overall response and PFS time (IRC evaluation) are presented by KRAS mutation status. Results: In general, the population with tissue available for KRAS analysis (n=233) was representative of the overall intention- to-treat population (n=337) in terms of demographic and efficacy parameters. KRAS mutations were detected in 42% (99/233) of evaluable samples. Conclusions: These data suggest that the benefit from addition of cetuximab to standard treatment is higher for the population with wild-type KRAS. For patients with KRAS mutations, no benefit could be shown of adding cetuximab to FOLFOX in this study. PFS and overall response rate (RR) by KRAS mutation status KRAS status Median PFS (mo) Cetuximab + FOLFOX Median PFS (mo) FOLFOX Overall RR (%) Cetuximab + FOLFOX Overall RR (%) FOLFOX Wild-type 7.7 (n=61) 7.2 (n=73) HR:0.57 p=0.02 61 (n=61) 37 (n=73) p=0.01 Mutation 5.5 (n=52) 8.6 (n=47) HR:1.83 p=0.02 33 (n=52) 49 (n=47) p=0.11 HR, hazard ratio. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Merck Serono Merck Merck, Merck Serono
Effect of consolidation with arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710
Authors: B. L. Powell
Journal: Journal of Clinical Oncology (2007)

2 Background: This randomized phase III study was designed to evaluate the benefit and toxicity of two 25-day courses of As 2 O 3 as first post-remission therapy for newly diagnosed patients with APL. Methods: Adult patients were randomized to receive 2 courses of As 2 O 3 (0.15 mg/kg/d for 5d each wk for 5 wk) as a first consolidation if they achieved remission (CR or PR) after induction with oral tretinoin (ATRA; 45 mg/m 2 /d), daunorubicin (50 mg/m 2 IV × 4d), and cytarabine (200 mg/m 2 CIV × 7d); by study design, all but 2 children were assigned to the non-As 2 O 3 arm. Subsequent consolidation on both arms included 2 courses of ATRA (45 mg/m 2 × 7d) + daunorubicin (50 mg/m 2 × 3d; 2d for age &lt; 15 yr). CR patients were then randomized to 1 yr of ATRA maintenance (7d repeated every other wk) with or without 6- mercaptopurine (daily) + methotrexate (weekly). Results: 518 adults (15–79 yr) and 64 children (&lt;15 yr; 11%) with untreated APL were enrolled by 5 cooperative groups (CALGB, ECOG, SWOG, COG, NCIC-CTG). Eligibility required demonstration of PML-RARA in one of 3 central labs; 37 adults and 7 children were ineligible and not included in the analyses. Patient characteristics and toxicity data have been reported (ASH 2006; Blood 108:171a). Median follow up is now 29 mos. Overall CR rate for adults was 89% and did not differ by treatment arm; CR rate for children was 89%. There were 41 deaths (8%) within 60 days. EFS, the primary endpoint, was 77% at 3 yrs on the As 2 O 3 arm (median, not reached) compared to 59% at 3 yrs on the standard arm (median, 63 mos; p=0.0013). Overall, 84% of adults were alive at last follow up. OS was 86% at 3 yrs on the As 2 O 3 arm compared to 77% at 3 yrs on the standard arm (medians not reached; p=0.029); EFS and OS for pediatric patients did not differ statistically from the adult arm without As 2 O 3 . Among 452 CR pts, there have been only 71 post-CR events (16%) so disease- free survival has not yet been analyzed by treatment arm. Conclusion: The addition of 2 courses of As 2 O 3 consolidation following remission induction significantly improves EFS and OS in adults with APL. No significant financial relationships to disclose.
TRAUMATIC CHYLOTHORAX: CASE REPORT
Authors: Joseph Gordon
Journal: Annals of Internal Medicine (1940)

Case Reports1 April 1940TRAUMATIC CHYLOTHORAX: CASE REPORTJOSEPH GORDON, M.D.JOSEPH GORDON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-13-10-1998 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTraumatic chylothorax is sufficiently uncommon to warrant an additional case report in the literature. The case here reported is the first instance of this condition observed in a series of 3,000 admissions to the tuberculosis division of this institution during a period of 10 years. One might justifiably expect that such cases, if they did occur at all frequently, would often find their way into an institution where diseases of the chest make up a major portion of the admissions.CASE REPORTN. O., a white male, aged 31 years, was admitted on August 11, 1937 on the advice of...References1. MCNABSCARLETT DSEP: Traumatic chylothorax due to intrathoracic rupture of thoracic duct, Canadian Med. Assoc. Jr., 1932, xxvii, 29-36. Google Scholar2. VAN NUYS RG: Chylothorax, Calif. and West. Med., 1931, xxxiv, 269-271. Google Scholar3. SHACKELFORDFISHER RTAM: Traumatic chylothorax, South. Med. Jr., 1938, xxxi, 7. Google Scholar4. FINKELSTEIN BK: Tears and injuries of the thoracic duct, Bolnichn. Gaz. Botkina, 1901, xxii, 914, 958. Google Scholar5. BEATTY OA: Chylothorax; case report, Jr. Thorac. Surg., 1936, vi, 221. CrossrefGoogle Scholar6. HEPPNER GJ: Bilateral chylothorax and chyloperitoneum, Jr. Am. Med. Assoc., 1934, cii, 1294. CrossrefGoogle Scholar7. LILLIEFox ORGW: Traumatic intrathoracic rupture of the thoracic duct with chylothorax, Ann. Surg., 1935, ci, 1367. CrossrefGoogle Scholar8. WALLISSCHÖLBERG RLHA: On chylous and pseudo-chylous ascites, Quart. Jr. Med., 1909, iii, 301. Google Scholar9. HALLMORGAN EHA: Case of chylous ascites, Quart. Bull. Northwestern Univ. Med. Sch., 1900, ii, 44. Google Scholar10. CUSHING H: Wounds of the thoracic duct, Ann. Surg., 1898, xxvii, 719. Google Scholar11. HARRISON E: Treatment of wounds of the thoracic duct, Brit. Jr. Surg., 1916, iv, 304. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Ray Brook, New York*Received for publication December 8, 1938.From the Tuberculosis Service of the Bergen County Hospital, Ridgewood, New Jersey. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byChylothoraxSpezielle Chirurgie der Erkrankungen und Verletzungen des ThoraxTraumatic chylothoraxTRAUMATIC CHYLOTHORAXTrauma of the thorax 1 April 1940Volume 13, Issue 10Page: 1998-2004KeywordsChylothoraxThorax ePublished: 1 December 2008 Issue Published: 1 April 1940 PDF downloadLoading ...
Pathogenesis of Reticulum Cell Sarcoma in Mice&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Richard Siegler, Marvin A. Rich
Journal: JNCI Journal of the National Cancer Institute (1968)

Journal Article Pathogenesis of Reticulum Cell Sarcoma in Mice Get access Richard Siegler, Richard Siegler Department of Experimental Pathology, Cancer Research Institute, New England Deaconess Hospital, Boston, Massachusetts 02215, and Department of Cell Biology, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141 Search for other works by this author on: Oxford Academic PubMed Google Scholar Marvin A. Rich Marvin A. Rich Department of Experimental Pathology, Cancer Research Institute, New England Deaconess Hospital, Boston, Massachusetts 02215, and Department of Cell Biology, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 41, Issue 1, July 1968, Pages 125–143, https://doi.org/10.1093/jnci/41.1.125 Published: 01 July 1968 Article history Received: 07 December 1967 Accepted: 28 February 1968 Published: 01 July 1968
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
Authors: R de Wit, G Stoter, S B Kaye, D T Sleijfer, W G Jones, W W ten Bokkel Huinink, L A Rea, L Collette, R Sylvester
Journal: Journal of Clinical Oncology (1997)

PURPOSE This prospective randomized trial was designed to compare the efficacy of etoposide plus cisplatin (EP) versus bleomycin, etoposide, and cisplatin (BEP) chemotherapy in patients with good-prognosis metastatic nonseminomatous testicular cancer. PATIENTS AND METHODS Four hundred nineteen patients with good-prognosis nonseminomatous testicular cancer were randomized to receive four cycles of cisplatin 20 mg/m2 on days 1 to 5 plus etoposide 120 mg/m2 on days 1, 3, and 5 with or without bleomycin 30 mg weekly. RESULTS Of 395 eligible patients, 169 of 195 patients allocated to EP (87%) and 189 of 200 patients allocated to BEP (95%) achieved a complete response with chemotherapy alone or after postchemotherapy surgery. These results are significantly different (P = .0075). After a median follow-up duration of 7.3 years, eight patients (4%) on each treatment arm relapsed. In view of the low number of unfavorable treatment outcomes (11%), no significant differences were detected in time to progression (P = .136) and survival (P = .262). Both the acute and late pulmonary toxicity and neurotoxicity were significantly greater in patients who received BEP, whereas Raynaud's phenomenon occurred exclusively in patients who received BEP (P &lt; .001). Two patients treated with BEP died of bleomycin pulmonary toxicity. CONCLUSION BEP is the most effective combination regimen in the treatment of disseminated nonseminomatous germ cell cancer. In this particular BEP regimen with etoposide at a dose of 360 mg/m2 per cycle, even in good-prognosis patients, bleomycin cannot be deleted without compromising treatment efficacy, but its use is associated with more toxicity (particularly pulmonary) and efforts to reduce this merit further exploration.
Abstract 3066: YPEL3, a novel inducer of senescence, is inhibited by estrogen in ER+ mammary tumor cells
Authors: Rebecca M. Tuttle, Kelly L. Miller, Paula M. Termulhen, Steven J. Berberich
Journal: Cancer Research (2010)

Abstract It was recently discovered by this laboratory that Yippie-like 3 (YPEL3) is a novel p53 regulated gene that when induced triggers premature senescence in primary and tumor cell lines. Initial screens of human tumor samples uncovered significant decreases in YPEL3 gene expression in ER- verses ER+ breast cancers leading us to believe that estrogen may have a regulatory effect on YPEL3 expression. Using ER+ MCF7 cells, we determined that estrogen is a significant inhibitor of YPEL3 gene expression in cells grown in media with 10% serum verses cells grown in media with charcoal stripped serum (CSS) from which estrogen has been removed. The increase in YPEL3 mRNA expression demonstrated in CSS can be blocked by the addition of estrogen, and as expected tamoxifen competes with this estrogen repressive effect. The effects of estrogen on YPEL3 expression are not observed in MCF10A mammary epithelial cells which are ER negative demonstrating the requirement for the estrogen receptor in the observed effect. Given our observation that YPEL3 induction triggers senescence in breast cancer cells, we employed beta-galactosidase activity as a measurement of senescence and observed an 8-fold increase in senescence in MCF7 cells grown in CSS media. The increase is reduced to less than 3.5-fold with the addition of estrogen to the CSS media, and the increase in cellular senescence is blocked in MCF7 cells stably selected for the loss of YPEL3 (MCF7-shYPEL3) suggesting the need for the absence of estrogen and the presence of YPEL3 in senescence induction. We are currently testing the effects of estrogen on MCF7 cells where p53 has been knocked down using RNAi approaches and are planning to test the effects of RNAi targeting ER-alpha. We believe estrogen is inhibiting YPEL3 expression through its association with the estrogen receptor and their association with p53 thereby inhibiting p53 transactivation of YPEL3. These findings suggest that modulation of YPEL3 by estrogen and its growth suppressive effects may provide a target for future breast cancer therapies. Note: First two authors contributed equally. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3066.
Anticipated Versus Actual Emotional Reactions to Disclosure of Results of Genetic Tests for Cancer Susceptibility: Findings From p53 and BRCA1 Testing Programs
Authors: Michel Dorval, Andrea Farkas Patenaude, Katherine A. Schneider, Stephanie A. Kieffer, Lisa DiGianni, Kathy J. Kalkbrenner, Jonas I. Bromberg, Laura A. Basili, Kathleen Calzone, Jill Stopfer, Barbara L. Weber, Judy E. Garber
Journal: Journal of Clinical Oncology (2000)

PURPOSE: We examined the ability of individuals undergoing genetic testing for cancer susceptibility in two structured research protocols to accurately anticipate emotional reactions to disclosure of their test result. We explored whether accuracy of emotional anticipation was associated with postdisclosure psychologic adjustment. METHODS: Data from 65 individuals were analyzed; 24 members of Li-Fraumeni cancer syndrome families were tested for p53 mutations (all 24 were unaffected), and 41 subjects with hereditary breast-ovarian cancer susceptibility were tested for BRCA1 mutations (34 were unaffected and seven were affected). Subjects were from families in which a germline mutation had been previously identified. At the pretest session, subjects rated the extent to which they anticipated feeling each of six emotional states (relief, happiness, sadness, guilt, anger, and worry) after disclosure that they did or did not carry the familial mutation. After receiving their test result, they rated their feelings on the same scale of emotions for the appropriate condition. Extent of accuracy and association with psychologic distress at 6 months, as assessed with standardized measures, were evaluated. RESULTS: Overall, mean levels of emotional reactions after receiving test results were not different from those anticipated before result disclosure. However, affected BRCA1 carriers experienced higher levels of anger and worry than they had anticipated. Underestimation of subsequent distress emotions related to test result was associated with a significant increase in general psychologic distress at 6 months. CONCLUSION: Unaffected individuals in cancer-predisposition testing programs are generally accurate in anticipating emotional reactions to test results. However, cancer patients may underestimate their distress after disclosure of positive results and could benefit from intervention strategies.
Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma
Authors: Shruti Bhatt, Julie Matthews, Salma Parvin, Kristopher A. Sarosiek, Dekuang Zhao, Xiaoyu Jiang, Elif Isik, Anthony Letai, Izidore S. Lossos
Journal: Blood (2015)
Assessing the risk of diabetes:
Authors: Rupal Shah
Journal: BMJ (2015)

#### The bottom line A 38 year old South Asian man comes to see you for a medication review. He takes bendroflumethiazide for hypertension, which is well controlled. His last recorded body mass index (BMI) was 29. As part of the review, you decide to discuss his risk of developing diabetes. This man is at high risk of diabetes because of his ethnicity, his hypertension, and his BMI; in general, obesity accounts for 80-85% of the risk of developing type 2 diabetes. In adults over 40 years, the risk of diabetes is two to three times greater in South Asians than in age matched white people.
Late-breaking abstract: Long-term efficacy of intensive behavior interventions and free medications for smoking cessation in Brazil
Authors: Ana Thereza Rocha, Marla Rocha, Marina Cabral, Lucas Macedo, Franklin Pompa-Filho, Manuela de Pinho
Journal: European Respiratory Journal (2011)

Introduction:  Treatment of tobacco dependence is associated with low long-term success rates, particularly in women. Our public clinic (NATTAB) offers intensive behavior interventions (IBI) program combined with free medications in Salvador.   Purpose:  To evaluate the long-term tobacco abstinence rates and gender differences in our IBI program combined with free medications.   Methods:  We evaluated consecutive smokers, clinical and psychologically, verified the Fagerstrom9s test (FT) score and offered IBI by a multidisciplinary team in group sessions (weekly x 4; then biweekly x 4 and monthly x 9). Coping skills and problem solving activities were developed. The rates of reported abstinence were evaluated by telephone contact or review of last visit on clinical charts, and compared by chi-square test.   Results:  467 patients were evaluated in 35 months, 350 initiated IBI, 85% of the patients used medications and had follow-up for 14±11 months (67% for 12 months). Mean age was 53±10 yrs, 67% were women and median FT score was 6 (IQR 3). 79% of women and 75% of men quit smoking at some point. The abstinence and relapse rates were repectively: 51% and 31% at 1-3 mo; 50% and 36% at 3-6 mo; 48 and 39% at 6-12 mo; 44% and 41% at 12-24 months and 42% and 42% at 24-35 months. Abstinence rates did not differ for men and women (45% vs. 51%, p=NS, respectively). Among those who relapsed, the mean time of abstinence was 3.6±4.1 months, and they stated that abandoning the IBI sessions contributed to relapse.   Conclusions:  Programs combining IBI with free medications can be effective for long-term smoking cessation despite moderate to high nicotine-dependence, independently of gender.